# TORL BioTherapeutics LLC

> TORL BioTherapeutics is a clinical-stage biopharmaceutical company in Culver City, California developing antibody-based cancer therapies, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Built on discoveries from the UCLA laboratory of Dennis Slamon - the scientist behind Herceptin and Ibrance - TORL is advancing a pipeline against novel cancer targets such as Claudin 6, Claudin 18.2, CDH17, and DLK1. Its lead program, TORL-1-23 (ixotatug vedotin), a CLDN6-targeted ADC, is in pivotal trials for platinum-resistant ovarian cancer. The company has raised over $450 million across multiple rounds, including a $96 million Series C in October 2025.

- **Founded:** 2019
- **Headquarters:** Culver City, California, United States
- **Founders:** Dennis Slamon (Scientific Co-founder & Board Member (UCLA)), David (Dave) Licata (Co-founder & President), Mark Attanasio (Co-founder (Managing Partner, Crescent Capital)), Neil O'Brien (Co-founder)
- **Team size:** ~63 employees
- **Products:** TORL-1-23 (ixotatug vedotin / Ixo-V), TORL-2-307, TORL-3-600, TORL-4-500, TORL-5-700
- **Notable:** Raised over $450 million in total financing since its 2019 founding, Closed a $96 million Series C in October 2025, TORL-1-23 received FDA Fast Track Designation

## Products & services

- **TORL-1-23 (ixotatug vedotin / Ixo-V)** — Lead Claudin 6 (CLDN6)-targeted antibody-drug conjugate. In pivotal CATALINA-2 Phase 2 for platinum-resistant ovarian cancer, with a confirmatory Phase 3 (CATALINA-3) initiating in 2026. Holds FDA Fast Track Designation.
- **TORL-2-307** — Both a monoclonal antibody (mAb) and an antibody-drug conjugate targeting Claudin 18.2 (CLDN18.2)-positive solid tumors such as gastric and pancreatic cancers.
- **TORL-3-600** — An ADC targeting CDH17 (cadherin 17) for CDH17-positive colorectal and gastrointestinal cancers.
- **TORL-4-500** — An ADC targeting Delta-like non-canonical Notch ligand 1 (DLK1)-positive solid tumors; in Phase 1.
- **TORL-5-700** — A preclinical program targeting an undisclosed hematology target.

## Achievements

- Raised over $450 million in total financing since its 2019 founding
- Closed a $96 million Series C in October 2025
- TORL-1-23 received FDA Fast Track Designation
- Reported a 50% overall response rate in CLDN6+ platinum-resistant ovarian cancer at the 2.4 mg/kg dose in Phase 1
- Advanced TORL-1-23 into a global pivotal Phase 2 (CATALINA-2) with Phase 3 planned for 2026
- Built a four-target clinical and preclinical pipeline from validated UCLA science

## Latest updates

- **2025-10** — Closed a $96 million Series C financing and presented updated TORL-1-23 Phase 1 results at the ESMO Congress in Berlin.
- **2025-01** — Advanced TORL-1-23 (ixotatug vedotin) into pivotal CATALINA-2 Phase 2 for platinum-resistant ovarian cancer.
- **2024-09** — Presented Phase 1 data showing up to 50% response rates in CLDN6+ platinum-resistant ovarian cancer at ESMO 2024.
- **2024-04** — Announced a $158 million oversubscribed Series B-2 financing to advance its ADC oncology pipeline.
- **2023-04** — Launched publicly with a $158 million Series B financing led by Goldman Sachs Asset Management.

## Links

- Website: https://torlbio.com
- LinkedIn: https://www.linkedin.com/company/torl-biotherapeutics-llc

---

Profile page: https://yespress.io/torl-biotherapeutics-llc
Published by YesPress — https://yespress.io
Last updated: 2026-06-10